KRAS-话题@MedSci

#KRAS#

78篇内容 | 11325人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2370965, encodeId=6d8423e0965bb, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=对话大咖 | 黄小兵教授：多款KRAS G12C抑制剂同台，如何为患者选出“最优解”？, objectType=article, longId=951913, objectId=e315951913ad, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250205/1738746672431_8538692.jpg, objectUrl=/article/show_article.do?id=e315951913ad, replyNumber=0, likeNumber=22, createdTime=2026-09-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e315951913ad, moduleTitle=对话大咖 | 黄小兵教授：多款KRAS G12C抑制剂同台，如何为患者选出“最优解”？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e315951913ad)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2369734, encodeId=ba042369e3465, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=f3be13e909de' target=_blank style='color:#2F92EE;'>#肺腺癌（LUAD）#</a> <a href='/topic/show?id=ddb01452991d' target=_blank style='color:#2F92EE;'>#丙氨酰-tRNA合成酶1（AARS1）#</a>, objectTitle=Cell Death & Differ：苏州大学徐春等发现AARS1成KRAS乳酸感应效应物，串联自噬失控与代谢重编程, objectType=article, longId=951527, objectId=707d95152e49, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20260901/6c64f85f178341c6980b7707806d03db-8CHtpZwEDwcL.jpg, objectUrl=/article/show_article.do?id=707d95152e49, replyNumber=0, likeNumber=14, createdTime=2026-09-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=安徽省, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2301088, encodeId=0ac52301088da, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=结直肠癌患者PCR初检KRAS G13D、复检Q61突变？NGS证实双突变或与更强抗EGFR耐药相关, objectType=article, longId=927068, objectId=fbf592e0685e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720149787150_5579292.png, objectUrl=/article/show_article.do?id=fbf592e0685e, replyNumber=0, likeNumber=105, createdTime=2026-02-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=fbf592e0685e, moduleTitle=结直肠癌患者PCR初检KRAS G13D、复检Q61突变？NGS证实双突变或与更强抗EGFR耐药相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbf592e0685e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2289712, encodeId=072f2289e1244, content=本研究通过GENERATE（JCOG1611）试验，对<a href='/topic/show?id=8c36934354a' target=_blank style='color:#2F92EE;'>#转移性胰腺癌#</a>一线治疗的三种主流化疗方案（<a href='/topic/show?id=d138132268d8' target=_blank style='color:#2F92EE;'>#mFOLFIRINOX#</a>、<a href='/topic/show?id=73e21322694f' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=73e21322694f' target=_blank style='color:#2F92EE;'>#S-IROX#</a></a>、<a href='/topic/show?id=f8371322e011' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=f8371322e011' target=_blank style='color:#2F92EE;'>#nab-paclitaxel+gemcitabine#</a></a>）进行了直接比较，研究设计严谨、多中心大样本且随机化分层合理，具有较高的临床证据级别。结果显示，<a href='/topic/show?id=f8371322e011' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=f8371322e011' target=_blank style='color:#2F92EE;'>#nab-paclitaxel+gemcitabine#</a></a>方案在总生存期（OS）上优于其他两种方案，同时胃肠道毒性更低，凸显出其对体能状态良好患者的临床优选价值。但<a href='/topic/show?id=73e21322694f' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=73e21322694f' target=_blank style='color:#2F92EE;'>#S-IROX#</a></a>组虽然客观缓解率（ORR）较高，却未能转化为生存优势，提示药效与临床转归关联复杂。不足之处及补充建议：目前文章仅强调了化疗方案的疗效与安全性，而未深入探讨<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a>在胰腺癌个体化治疗中的指导意义。建议增加基于基因检测（如<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>变异、<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>驱动）的疗法前景评述。文章未涉及<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a>及<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>的近期进展及其在特定人群中的可行性，补充相关临床试验数据能更完善决策参考。建议补充<a href='/topic/show?id=d735e2637ee' target=_blank style='color:#2F92EE;'>#真实世界数据#</a>与患者预后因素分析，如<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>、合并症、肿瘤负荷等对疗效与毒性的影响，提升结果外推价值。综上，该文在为临床医师选择<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>一线治疗方案提供了重要依据，但进一步结合分子分型和精准医疗理念，将推动个体化治疗的临床实践发展。, objectTitle=J Clin Oncol：转移性胰腺癌一线治疗方案之争，孰优孰劣？, objectType=article, longId=891167, objectId=6a6a89116e39, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240702/1719885352231_92910.jpg, objectUrl=/article/show_article.do?id=6a6a89116e39, replyNumber=1, likeNumber=131, createdTime=2025-11-20, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=6a6a89116e39, moduleTitle=J Clin Oncol：转移性胰腺癌一线治疗方案之争，孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6a89116e39)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2276131, encodeId=af8422e6131bb, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a> <a href='/topic/show?id=919712914187' target=_blank style='color:#2F92EE;'>#siRNAs#</a>, objectTitle=JCI & Cancer Cell：癌症治疗新突破！科学家开发出具有双靶向作用的RNAi分子, objectType=article, longId=890287, objectId=727289028ef4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250805/1754370746789_1938376.png, objectUrl=/article/show_article.do?id=727289028ef4, replyNumber=0, likeNumber=107, createdTime=2025-08-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2263689, encodeId=45382263689e5, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=5398e54928c' target=_blank style='color:#2F92EE;'>#突变#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Cancer Res：科学家揭秘结直肠癌的“基因密码”，遗传背景如何影响肿瘤突变？, objectType=article, longId=874868, objectId=1ba18e486853, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250505/1746459668708_1938376.png, objectUrl=/article/show_article.do?id=1ba18e486853, replyNumber=0, likeNumber=135, createdTime=2025-05-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2262492, encodeId=e295226249225, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=e2d6126425db' target=_blank style='color:#2F92EE;'>#PIKfyve#</a> <a href='/topic/show?id=c95711284ca' target=_blank style='color:#2F92EE;'>#MAPK#</a>, objectTitle=Nature：同时靶向PIKfyve和KRAS-MAPK可在临床前模型中根除胰腺癌, objectType=article, longId=873639, objectId=53c58e36399a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250426/1745626601898_2185383.png, objectUrl=/article/show_article.do?id=53c58e36399a, replyNumber=0, likeNumber=141, createdTime=2025-04-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2243391, encodeId=6f622243391a6, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=绘真约大咖 | 姜丽教授：多角度了解非小细胞肺癌的新晋“明星”靶点KRAS, objectType=article, longId=855901, objectId=430f855901e7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241218/1734517321800_8538692.jpg, objectUrl=/article/show_article.do?id=430f855901e7, replyNumber=0, likeNumber=143, createdTime=2024-12-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=430f855901e7, moduleTitle=绘真约大咖 | 姜丽教授：多角度了解非小细胞肺癌的新晋“明星”靶点KRAS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=430f855901e7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2227756, encodeId=58ac222e756d4, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=dc6f11953280' target=_blank style='color:#2F92EE;'>#TRA2β#</a>, objectTitle=2024年9月Science期刊精华, objectType=article, longId=844798, objectId=f9a1844e98a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240924/1727131940301_2185383.png, objectUrl=/article/show_article.do?id=f9a1844e98a6, replyNumber=0, likeNumber=137, createdTime=2024-09-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2227436, encodeId=8615222e436c1, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=c6f814e5136' target=_blank style='color:#2F92EE;'>#PROTAC#</a> <a href='/topic/show?id=f259105e132a' target=_blank style='color:#2F92EE;'>#蛋白降解剂#</a> <a href='/topic/show?id=bace119481df' target=_blank style='color:#2F92EE;'># ACBI3 #</a>, objectTitle=Science：新研究表明小分子泛KRAS降解剂有望治疗之前难以治疗的癌症, objectType=article, longId=844549, objectId=214a8445497d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240924/1727130706532_2185383.png, objectUrl=/article/show_article.do?id=214a8445497d, replyNumber=0, likeNumber=143, createdTime=2024-09-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2226850, encodeId=8572222685066, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征, objectType=article, longId=844002, objectId=b959844002ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719567809676_92910.png, objectUrl=/article/show_article.do?id=b959844002ce, replyNumber=0, likeNumber=0, createdTime=2024-09-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b959844002ce, moduleTitle=KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b959844002ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2225505, encodeId=33dc2225505f8, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=抗癌新药IBI351疗效数据出炉，近50%的KRAS基因突变患者病灶缩小30%！, objectType=article, longId=841981, objectId=ca95841981bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720362208683_5579292.jpg, objectUrl=/article/show_article.do?id=ca95841981bd, replyNumber=0, likeNumber=178, createdTime=2024-09-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ca95841981bd, moduleTitle=抗癌新药IBI351疗效数据出炉，近50%的KRAS基因突变患者病灶缩小30%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca95841981bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222456, encodeId=a8d6222245636, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=c9601046520d' target=_blank style='color:#2F92EE;'>#RAS通路#</a>, objectTitle=RAS癌症靶向治疗的药物开发, objectType=article, longId=840585, objectId=d9ae84058549, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240717/1721179050397_8538692.jpg, objectUrl=/article/show_article.do?id=d9ae84058549, replyNumber=0, likeNumber=166, createdTime=2024-08-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d9ae84058549, moduleTitle=RAS癌症靶向治疗的药物开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9ae84058549)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2221103, encodeId=5595222110322, content=<a href='/topic/show?id=fd55839636c' target=_blank style='color:#2F92EE;'>#胰腺导管腺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=95ad1180325e' target=_blank style='color:#2F92EE;'>#分子残留疾病#</a>, objectTitle=担心胰腺癌术后“卷土重来”，肿瘤知情ctDNA-MRD针对I-III期患者均能预测复发风险, objectType=article, longId=839454, objectId=3878839454d1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240816/1723804453430_8538692.png, objectUrl=/article/show_article.do?id=3878839454d1, replyNumber=0, likeNumber=0, createdTime=2024-08-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3878839454d1, moduleTitle=担心胰腺癌术后“卷土重来”，肿瘤知情ctDNA-MRD针对I-III期患者均能预测复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3878839454d1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208097, encodeId=15f3220809ece, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Nat Commun：中南大学金鑫/华中科技大学江科/唐露发现KRAS加速胰腺癌进展的新机制, objectType=article, longId=828460, objectId=51708284601f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240603/1717401736041_5579292.png, objectUrl=/article/show_article.do?id=51708284601f, replyNumber=0, likeNumber=207, createdTime=2024-06-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=51708284601f, moduleTitle=Nat Commun：中南大学金鑫/华中科技大学江科/唐露发现KRAS加速胰腺癌进展的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51708284601f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200624, encodeId=eec5220062477, content=<a href='/topic/show?id=3263e877271' target=_blank style='color:#2F92EE;'>#结肠癌#</a> <a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=39f313935c9' target=_blank style='color:#2F92EE;'>#PDAC#</a>, objectTitle=读书报告 | AMPLIFY-201研究：淋巴结靶向性KRAS疫苗治疗胰腺癌和结肠癌的I期临床研究, objectType=article, longId=822756, objectId=8626822e560c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-team-discussing-together-in-the-hallway-PJWSSDB.jpg, objectUrl=/article/show_article.do?id=8626822e560c, replyNumber=0, likeNumber=1121, createdTime=2024-04-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=8626822e560c, moduleTitle=读书报告 | AMPLIFY-201研究：淋巴结靶向性KRAS疫苗治疗胰腺癌和结肠癌的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8626822e560c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190568, encodeId=5fb7219056843, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=257b109431a' target=_blank style='color:#2F92EE;'>#LKB1#</a> <a href='/topic/show?id=3958111826cf' target=_blank style='color:#2F92EE;'>#STK11#</a>, objectTitle=KRAS突变的肿瘤预后如何？STK11/LKB1基因会来捣乱缩短生存期！, objectType=article, longId=814568, objectId=bf32814568c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-at-work-PM2PHLF.jpg, objectUrl=/article/show_article.do?id=bf32814568c7, replyNumber=0, likeNumber=233, createdTime=2024-03-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bf32814568c7, moduleTitle=KRAS突变的肿瘤预后如何？STK11/LKB1基因会来捣乱缩短生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf32814568c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188928, encodeId=a97d218892870, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a> <a href='/topic/show?id=93df1025e1f6' target=_blank style='color:#2F92EE;'>#高级别浆液性卵巢癌#</a>, objectTitle=基因检测检出KRAS/TP53共突变，识破高级别浆液性卵巢癌的“低级别”伪装, objectType=article, longId=814432, objectId=804581443283, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=804581443283, replyNumber=0, likeNumber=239, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=804581443283, moduleTitle=基因检测检出KRAS/TP53共突变，识破高级别浆液性卵巢癌的“低级别”伪装, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=804581443283)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181538, encodeId=0c3d218153872, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=7692105e040' target=_blank style='color:#2F92EE;'>#KRAS抑制剂#</a>, objectTitle=KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......, objectType=article, longId=809328, objectId=7427809328dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240113/8450c162a88d45379bdf9761f1c07713.jpg, objectUrl=/article/show_article.do?id=7427809328dc, replyNumber=0, likeNumber=232, createdTime=2024-01-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=7427809328dc, moduleTitle=KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7427809328dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177468, encodeId=b07d21e74682a, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a> <a href='/topic/show?id=f7171092493c' target=_blank style='color:#2F92EE;'>#深度突变扫描#</a> <a href='/topic/show?id=eb3e10925002' target=_blank style='color:#2F92EE;'>#变构位点#</a>, objectTitle=Nature：重大进展！新研究揭示在癌症中经常发生突变的KRAS蛋白的秘密弱点, objectType=article, longId=805993, objectId=460f80599394, topicUrl=null, isHasObj=0, objectCover=https://msimg.bioon.com/bioon-com/20231220/1703002108990_2185383.png, objectUrl=/article/show_article.do?id=460f80599394, replyNumber=0, likeNumber=147, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯话题小助手

KRAS

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS#

对话大咖 | 黄小兵教授：多款KRAS G12C抑制剂同台，如何为患者选出“最优解”？

2026-09-17发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #肺腺癌（LUAD）# #丙氨酰-tRNA合成酶1（AARS1）#

2026-09-16发表于安徽省

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #KRAS#

结直肠癌患者PCR初检KRAS G13D、复检Q61突变？NGS证实双突变或与更强抗EGFR耐药相关

2026-02-20发表于陕西省

侠胆医心 (审核中...)

前往app查看评论内容

全文收起本研究通过GENERATE（JCOG1611）试验，对#转移性胰腺癌#一线治疗的三种主流化疗方案（#mFOLFIRINOX#、#S-IROX#、#nab-paclitaxel+gemcitabine#）进行了直接比较，研究设计严谨、多中心大样本且随机化分层合理，具有较高的临床证据级别。结果显示，#nab-paclitaxel+gemcitabine#方案在总生存期（OS）上优于其他两种方案，同时胃肠道毒性更低，凸显出其对体能状态良好患者的临床优选价值。但 #S-IROX#组虽然客观缓解率（ORR）较高，却未能转化为生存优势，提示药效与临床转归关联复杂。不足之处及补充建议：目前文章仅强调了化疗方案的疗效与安全性，而未深入探讨#生物标志物#在胰腺癌个体化治疗中的指导意义。建议增加基于基因检测（如#BRCA#变异、#KRAS#驱动）的疗法前景评述。文章未涉及#免疫治疗#及#分子靶向药物#的近期进展及其在特定人群中的可行性，补充相关临床试验数据能更完善决策参考。建议补充#真实世界数据#与患者预后因素分析，如#糖尿病#、合并症、肿瘤负荷等对疗效与毒性的影响，提升结果外推价值。综上，该文在为临床医师选择#胰腺癌#一线治疗方案提供了重要依据，但进一步结合分子分型和精准医疗理念，将推动个体化治疗的临床实践发展。

J Clin Oncol：转移性胰腺癌一线治疗方案之争，孰优孰劣？

2025-11-20发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #MYC# #siRNAs#

2025-08-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #突变# #KRAS#

2025-05-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #KRAS# #PIKfyve# #MAPK#

2025-04-27发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #KRAS#

绘真约大咖 | 姜丽教授：多角度了解非小细胞肺癌的新晋“明星”靶点KRAS

2024-12-18发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#造血干细胞# #KRAS# #TRA2β#

2024-09-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #PROTAC# #蛋白降解剂# # ACBI3 #

2024-09-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #KRAS#

KRAS G12C突变非小细胞肺癌患者的临床、病理和分子特征

2024-09-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #KRAS#

抗癌新药IBI351疗效数据出炉，近50%的KRAS基因突变患者病灶缩小30%！

2024-09-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #RAS通路#

RAS癌症靶向治疗的药物开发

2024-08-26发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺导管腺癌# #KRAS# #分子残留疾病#

担心胰腺癌术后“卷土重来”，肿瘤知情ctDNA-MRD针对I-III期患者均能预测复发风险

2024-08-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #KRAS#

Nat Commun：中南大学金鑫/华中科技大学江科/唐露发现KRAS加速胰腺癌进展的新机制

2024-06-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结肠癌# #胰腺癌# #CRC# #KRAS# #PDAC#

读书报告 | AMPLIFY-201研究：淋巴结靶向性KRAS疫苗治疗胰腺癌和结肠癌的I期临床研究

2024-04-26发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #KRAS# #LKB1# #STK11#

KRAS突变的肿瘤预后如何？STK11/LKB1基因会来捣乱缩短生存期！

2024-03-02发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #TP53# #高级别浆液性卵巢癌#

基因检测检出KRAS/TP53共突变，识破高级别浆液性卵巢癌的“低级别”伪装

2024-02-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #KRAS# #KRAS抑制剂#

KRAS突变抑制剂最新汇总与对比：肺癌，胰腺癌，结直肠癌......

2024-01-14发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS# #深度突变扫描# #变构位点#

2023-12-27发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务